Scandion Oncology has announced that Johnny Stilou has been appointed as the company’s new CFO, and joins the company, effective no later than August 1, 2021.
He has a long experience from both Danish and international listed companies – most recently Nuevolution AB and Amgen Inc, states the company in a press release. Johnny Stilou succeeds Carit Jacques Andersen, who wishes to pursue a career outside Scandion Oncology.
“I am very pleased that we have attracted Johnny Stilou to Scandion Oncology. We are evolving the company and we need a focused capital market strategy in order to fund our operations optimally and secure a strong investor base. Johnny will bring a steady hand on the steering wheel with all the attributes required for a successful implementation of our capital market strategy,” says Bo Rode Hansen.
CFO of Nuevolution
Johnny Stilou’s financial background includes positions as CFO of Nuevolution (acquired by Amgen Inc.) and EVP & CFO of Veloxis Pharmaceuticals. Johnny has a successful track record of leading finance organizations in listed main market companies at Nasdaq as well as in-depth experience with capital markets and corporate finance, the company states.